vs
爱尔康（ALC）与艾伯维（ARGX）财务数据对比。点击上方公司名可切换其他公司
爱尔康的季度营收约是艾伯维的1.0倍（$2.6B vs $2.5B），艾伯维净利率更高（35.5% vs 6.8%，领先28.7%），艾伯维同比增速更快（83.2% vs 4.0%）
爱尔康是瑞美合资的制药及医疗器械企业，专注于眼健康护理产品领域。公司注册地为瑞士弗里堡州，全球总部设于日内瓦，核心运营基地位于美国得克萨斯州沃思堡，当地员工规模约4500人。
艾伯维是总部位于美国伊利诺伊州北芝加哥的制药企业，研发生产的药物覆盖多种疾病治疗领域，可满足多元临床需求，致力于为全球不同病症的患者提供可靠的治疗方案选择。
ALC vs ARGX — 直观对比
营收规模更大
ALC
是对方的1.0倍
$2.5B
营收增速更快
ARGX
高出79.2%
4.0%
净利率更高
ARGX
高出28.7%
6.8%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.6B | $2.5B |
| 净利润 | $176.0M | $877.2M |
| 毛利率 | 53.5% | 89.5% |
| 营业利润率 | 9.5% | 28.9% |
| 净利率 | 6.8% | 35.5% |
| 营收同比 | 4.0% | 83.2% |
| 净利润同比 | -21.1% | 1.3% |
| 每股收益（稀释后） | $0.35 | $13.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALCARGX
| Q4 25 | — | $2.5B | ||
| Q2 25 | $2.6B | $1.8B | ||
| Q4 24 | — | $1.4B | ||
| Q2 24 | $2.5B | $901.9M | ||
| Q2 23 | $2.4B | $510.9M | ||
| Q2 22 | $2.2B | — |
净利润ALCARGX
| Q4 25 | — | $877.2M | ||
| Q2 25 | $176.0M | $414.8M | ||
| Q4 24 | — | $865.6M | ||
| Q2 24 | $223.0M | $-32.5M | ||
| Q2 23 | $169.0M | $-123.2M | ||
| Q2 22 | $148.0M | — |
毛利率ALCARGX
| Q4 25 | — | 89.5% | ||
| Q2 25 | 53.5% | 89.2% | ||
| Q4 24 | — | 90.2% | ||
| Q2 24 | 55.0% | 89.4% | ||
| Q2 23 | 56.3% | 91.7% | ||
| Q2 22 | 54.3% | — |
营业利润率ALCARGX
| Q4 25 | — | 28.9% | ||
| Q2 25 | 9.5% | 19.2% | ||
| Q4 24 | — | 8.7% | ||
| Q2 24 | 12.7% | -15.4% | ||
| Q2 23 | 11.1% | -40.3% | ||
| Q2 22 | 9.0% | — |
净利率ALCARGX
| Q4 25 | — | 35.5% | ||
| Q2 25 | 6.8% | 23.4% | ||
| Q4 24 | — | 64.1% | ||
| Q2 24 | 8.9% | -3.6% | ||
| Q2 23 | 7.0% | -24.1% | ||
| Q2 22 | 6.7% | — |
每股收益（稀释后）ALCARGX
| Q4 25 | — | $13.25 | ||
| Q2 25 | $0.35 | $6.32 | ||
| Q4 24 | — | $13.33 | ||
| Q2 24 | $0.45 | $-0.55 | ||
| Q2 23 | $0.34 | $-2.21 | ||
| Q2 22 | $0.30 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $3.5B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $22.1B | $7.3B |
| 总资产 | $31.4B | $8.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALCARGX
| Q4 25 | — | $3.5B | ||
| Q2 25 | $1.4B | $2.1B | ||
| Q4 24 | — | $1.5B | ||
| Q2 24 | $1.4B | $1.4B | ||
| Q2 23 | $661.0M | $1.1B | ||
| Q2 22 | $1.0B | — |
总债务ALCARGX
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | $11.0M | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
股东权益ALCARGX
| Q4 25 | — | $7.3B | ||
| Q2 25 | $22.1B | $6.1B | ||
| Q4 24 | — | $5.5B | ||
| Q2 24 | $20.9B | $4.3B | ||
| Q2 23 | $19.9B | $2.9B | ||
| Q2 22 | $19.5B | — |
总资产ALCARGX
| Q4 25 | — | $8.7B | ||
| Q2 25 | $31.4B | $7.2B | ||
| Q4 24 | — | $6.2B | ||
| Q2 24 | $29.7B | $4.8B | ||
| Q2 23 | $29.2B | $3.2B | ||
| Q2 22 | $27.7B | — |
负债/权益比ALCARGX
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | 0.00× | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $323.3M |
| 自由现金流经营现金流 - 资本支出 | — | $322.4M |
| 自由现金流率自由现金流/营收 | — | 13.0% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | 0.37× |
| 过去12个月自由现金流最近4个季度 | — | $594.5M |
8季度趋势，按日历期对齐
经营现金流ALCARGX
| Q4 25 | — | $323.3M | ||
| Q2 25 | — | $361.8M | ||
| Q4 24 | — | $41.9M | ||
| Q2 24 | — | $-124.7M | ||
| Q2 23 | — | $-285.4M | ||
| Q2 22 | — | — |
自由现金流ALCARGX
| Q4 25 | — | $322.4M | ||
| Q2 25 | — | $356.6M | ||
| Q4 24 | — | $40.9M | ||
| Q2 24 | — | $-125.5M | ||
| Q2 23 | — | $-285.9M | ||
| Q2 22 | — | — |
自由现金流率ALCARGX
| Q4 25 | — | 13.0% | ||
| Q2 25 | — | 20.1% | ||
| Q4 24 | — | 3.0% | ||
| Q2 24 | — | -13.9% | ||
| Q2 23 | — | -56.0% | ||
| Q2 22 | — | — |
资本支出强度ALCARGX
| Q4 25 | — | 0.0% | ||
| Q2 25 | — | 0.3% | ||
| Q4 24 | — | 0.1% | ||
| Q2 24 | — | 0.1% | ||
| Q2 23 | — | 0.1% | ||
| Q2 22 | — | — |
现金转化率ALCARGX
| Q4 25 | — | 0.37× | ||
| Q2 25 | — | 0.87× | ||
| Q4 24 | — | 0.05× | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
